Cure51 raises a €15 million seed round led by Sofinnova Partners to harness the natural power of cancer survivors and contribute to curing the disease.

Mar 20, 2024•over 1 year ago

Amount Raised

€15 Million

Round Type

seed

ParisMedicalBiotechnologyHealth Care

Investors

Olivier PomelXavier NielLife Extension VenturesHitachi Ventures Gmb HSofinnova Partners

Description

Cure51 announced a successful €15 million seed funding round led by Sofinnova Partners. Other investors included Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog. The funding will enable Cure51 to build a unique cohort exploring the molecular processes by which certain cancer patients survive for extended periods despite having highly aggressive forms of the disease.

Company Information

Company

Cure51

Location

Paris, Ile De France, France

About

Cure51 is a French "TechBio" company founded by Nicolas Wolikow and Simon Istolainen, alongside seasoned entrepreneurs and four world-renowned oncology centers: Gustave Roussy Institute (IGR, Paris - France ), Leon Bérard Center (CLB, Lyon - France ), Charité Universitätsmedizin ( Berlin - Germany ) and Vall d' Hebron (VHIO, Barcelona - Spain ). The collaboration between the private and public sectors is at the core of the Cure51 project, led by a passionate team with expertise in computing, medicine, and biology, and partnered with principal investigators across its network of over 50 leading oncology centers worldwide.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends